Abstract
Neutropenia is a significant dose-limiting toxicity of cancer chemotherapy, especially in dose-intensified regimens. It is widely treated by injections of Granulocyte Colony-Stimulating Factor (G-CSF). However, optimal schedules of G-CSF administration are still not determined. In order to aid in identifying more efficacious and less neutropenic treatment protocols, we studied a detailed physiologically-based computer model of granulopoiesis, as affected by different treatment schedules of doxorubicin and/or Granulocyte Colony-Stimulating Factor (G-CSF). We validated the model as evident from accurate prediction of clinical data on human granulopoiesis in healthy individuals and in doxorubicin-treated cancer patients, with or without G-CSF support. Based on our model, we suggest new G-CSF administration regimens. These regimens include reduced G-CSF doses, optimally timed post-chemotherapy. Application of these regimens can lead to minimization of G-CSF side effects, as well as more cost-effective and less myelotoxic protocols. Currently clinical trials are being designed in order to test these new treatment regimens.
Original language | English |
---|---|
Pages (from-to) | 70-80 |
Number of pages | 11 |
Journal | Mathematical Modelling of Natural Phenomena |
Volume | 1 |
Issue number | 2 |
DOIs | |
State | Published - Jan 2006 |
Externally published | Yes |
Keywords
- chemotherapy
- granulopoiesis
- mathematical modeling
- treatment optimization
ASJC Scopus subject areas
- Modeling and Simulation
- Applied Mathematics